双特异的BCMA/CD24CAR-T细胞控制多发性骨髓瘤的生长
Fumou Sun1, Yan Cheng1, Visanu Wanchai1
1Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Nature communications
|January 19, 2024
概括
新的仿真抗原受体 (CAR) 针对CD24的T细胞疗法显示出治疗多发性骨髓瘤的前景. 这些CD24-CAR-T细胞增强了巨细胞对残留癌细胞的清除,改善了现有的BCMA-CAR-T治疗方法.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 针对抗B细胞成熟抗原 (BCMA) 特定的化学抗原受体 (CAR) T细胞疗法为多发性骨髓瘤提供了高响应率,但很少实现持久治愈.
- 复发通常是由最小的残留骨髓瘤细胞驱动的,具有较少的差异化,类似干细胞的特征,包括CD24表达.
- CD24阳性髓瘤细胞构成了BCMA-CAR-T治疗后残留疾病的重要部分.
研究的目的:
- 开发和评估特定于CD24的CAR-T细胞,以向和消除剩余的多发性髓瘤细胞.
- 研究CD24-CAR-T细胞增强髓瘤细胞清除的机制.
- 为了评估双重向的BCMA-CD24-CAR-T疗法的疗效,与单一的方法相比.
主要方法:
- 开发特定于CD24的CAR T细胞.
- 评估CD24-CAR-T细胞与髓瘤细胞和巨细胞的相互作用.
- 评估巨细胞两极分化和细胞活动.
- 双重向的BCMA-CD24-CAR-T细胞与单一的BCMA-CAR-T细胞在体外/体内模型中的比较.
主要成果:
- CD24-CAR-T细胞有效地阻断了CD24-Siglec-10通路,增强了髓瘤细胞的巨细胞介导的细胞形成.
- CD24-CAR-T细胞治疗促进了巨细胞向M1类表型的两极分化.
- 与单独使用的BCMA-CAR-T细胞相比,双重向的BCMA-CD24-CAR-T细胞显示出更高的疗效.
结论:
- CD24-CAR-T细胞代表了一种针对残留多发性髓瘤的新型免疫治疗策略.
- 这种方法通过促进巨细胞介导的瘤细胞清除来增强抗髓瘤免疫力.
- 双重向BCMA和CD24为改善多发性骨髓瘤治疗中的持久反应提供了一个有希望的途径.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

